Wall Street analysts expect that ADMA Biologics Inc (NASDAQ:ADMA) will announce ($0.31) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for ADMA Biologics’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.32). ADMA Biologics reported earnings per share of $0.59 during the same quarter last year, which would indicate a negative year over year growth rate of 152.5%. The company is scheduled to issue its next quarterly earnings report on Friday, November 2nd.
On average, analysts expect that ADMA Biologics will report full-year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.26). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.93) to $0.00. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.66 million for the quarter, compared to analyst estimates of $5.35 million.
A number of brokerages recently weighed in on ADMA. ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. LADENBURG THALM/SH SH dropped their price objective on ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday, June 13th. Oppenheimer began coverage on ADMA Biologics in a report on Thursday, July 12th. They set a “buy” rating and a $13.00 price objective on the stock. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of ADMA Biologics in a report on Wednesday, September 5th. Seven equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $9.50.
A number of institutional investors and hedge funds have recently bought and sold shares of ADMA. Millennium Management LLC boosted its position in ADMA Biologics by 254.0% during the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 48,455 shares in the last quarter. BlackRock Inc. boosted its position in ADMA Biologics by 59.5% during the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 15,115 shares in the last quarter. Spark Investment Management LLC purchased a new stake in ADMA Biologics during the first quarter worth $102,000. JPMorgan Chase & Co. purchased a new stake in shares of ADMA Biologics in the first quarter valued at $182,000. Finally, Element Capital Management LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at $118,000. Institutional investors own 55.08% of the company’s stock.
ADMA stock traded up $0.01 on Friday, reaching $6.58. 40 shares of the company’s stock were exchanged, compared to its average volume of 171,372. ADMA Biologics has a twelve month low of $2.01 and a twelve month high of $6.96. The firm has a market capitalization of $300.80 million, a PE ratio of -3.45 and a beta of 2.35. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: How is an ETF different from a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.